Hyaluronic acid-modified cationic nanoparticles overcome enzyme CYP1B1-mediated breast cancer multidrug resistance

被引:18
|
作者
Zhang, Jun [1 ]
Song, Jia [1 ]
Liang, Xiao [1 ]
Yin, Yunzhi [1 ]
Zuo, Tiantian [1 ]
Chen, Daijie [1 ]
Shen, Qi [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Pharm, 800 Dongchuan Rd, Shanghai 200240, Peoples R China
关键词
alpha-napthtoflavone; breast cancer; CD44; CYP1B1; DTX; hyaluronic acid; lysosome escape; multidrug resistance; nanoparticles; polyethyleneimine; MESOPOROUS SILICA; ANTICANCER DRUGS; DELIVERY; DOCETAXEL; MICELLES; CYP1B1; CYTOCHROME-P450; PACLITAXEL; CELLS; FORMULATIONS;
D O I
10.2217/nnm-2018-0244
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Aim: Enzyme CYP1B1 (CYP1B1) is usually overexpressed in multidrug resistance (MDR) breast cancer cells, which could metabolically inactivate docetaxel (DTX). Materials & methods: The cationic core-shell nanoparticles (hyaluronic acid/polyethyleneimine nanoparticles[HA/PEI NPs]) modified with hyaluronic acid (HA) were developed and coloaded with DTX and alpha-napthtoflavone (ANF, a CYP1B1 inhibitor) to overcome MDR in breast cancer induced by CYP1B1. Physicochemical characterization, MDR reversing effect in vitro and pharmacokinetics in vivo of HA/PEI NPs were evaluated. Results: The HA/PEI NPs exhibited spherical morphology with size of (193.6 +/- 3.1) nm. The HA/PEI NPs could reverse MDR effectively by downregulating the expression of CYP1B1. The HA/PEI NPs improved the bioavailability of DTX. Conclusion:The HA/PEI NPs might be a promising strategy to overcome CYP1B1-mediated breast cancer MDR. [GRAPHICS]
引用
收藏
页码:447 / 464
页数:18
相关论文
共 50 条
  • [1] Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance
    Zhong, Ping
    Chen, Xuehong
    Guo, Rishuo
    Chen, Xiaomei
    Chen, Zhihao
    Wei, Cui
    Li, Yusheng
    Wang, Wanting
    Zhou, Yi
    Qin, Linghao
    MOLECULAR PHARMACEUTICS, 2020, 17 (04) : 1114 - 1126
  • [2] Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1-mediated metabolism to the product 4′ hydroxy tangeretin
    Surichan, Somchaiya
    Arroo, Randolph R.
    Tsatsakis, Aristidis M.
    Androutsopoulos, Vasilis P.
    TOXICOLOGY IN VITRO, 2018, 50 : 274 - 284
  • [3] Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer
    Wang, Fang
    Li, Li
    Liu, Bo
    Chen, Zhen
    Li, Changzhong
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 86 : 595 - 604
  • [4] ZNF276 promotes the malignant phenotype of breast carcinoma by activating the CYP1B1-mediated Wnt/β-catenin pathway
    Ting Lei
    Wenwu Zhang
    Yongyin He
    Shi Wei
    Xiaoyu Song
    Yi Zhu
    Guoqing Luo
    Zhenzhan Kuang
    Guanjie Li
    Quan Zhou
    Zhaohui Sun
    Bin Xiao
    Linhai Li
    Cell Death & Disease, 13
  • [5] ZNF276 promotes the malignant phenotype of breast carcinoma by activating the CYP1B1-mediated Wnt/β-catenin pathway
    Lei, Ting
    Zhang, Wenwu
    He, Yongyin
    Wei, Shi
    Song, Xiaoyu
    Zhu, Yi
    Luo, Guoqing
    Kuang, Zhenzhan
    Li, Guanjie
    Zhou, Quan
    Sun, Zhaohui
    Bin Xiao
    Li, Linhai
    CELL DEATH & DISEASE, 2022, 13 (09)
  • [6] Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells
    Safaei, Mohsen
    Khosravian, Pegah
    Sheykhshabani, Sedighe Kazemi
    Mardani, Gashtasb
    Elahian, Fatemeh
    Mirzaei, Seyed Abbas
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2022, 441
  • [7] Co-Delivery of Paclitaxel and shMCL-1 by Folic Acid-Modified Nonviral Vector to Overcome Cancer Chemotherapy Resistance
    Nie, Wen
    Wang, Bilan
    Mi, Xue
    Chen, Jing
    Yu, Ting
    Miao, Junming
    Lin, Yunzhu
    Yang, Tingting
    Ran, Mengni
    Hong, Zehuo
    Liu, Xiaoxiao
    Liang, Xiao
    Qian, Zhiyong
    Gao, Xiang
    SMALL METHODS, 2021, 5 (05)
  • [8] LncRNA UCA1 Enhances Cisplatin Resistance by Regulating CYP1B1-mediated Apoptosis via miR-513a-3p in Human Gastric Cancer
    Cheng, Haidong
    Sharen, Gaowa
    Wang, Zhaoyang
    Zhou, Jing
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 367 - 377
  • [9] α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship
    Chen, Peng
    Wang, Shaobing
    Cao, Chenyang
    Ye, Wenchong
    Wang, Meizhu
    Zhou, Cui
    Chen, Wenming
    Zhang, Xu
    Zhang, Keyu
    Zhou, Wen
    BIOORGANIC CHEMISTRY, 2021, 116
  • [10] α1-Acid Glycoprotein-Decorated Hyaluronic Acid Nanoparticles for Suppressing Metastasis and Overcoming Drug Resistance Breast Cancer
    Omar, Haneen
    Fardous, Roa'
    Alhindi, Yasser M.
    Aodah, Alhassan H.
    Alyami, Mram
    Alsuabeyl, Mohammed S.
    Alghamdi, Waleed M.
    Alhasan, Ali H.
    Almalik, Abdulaziz
    BIOMEDICINES, 2022, 10 (02)